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Abstract
Background: SUN(^_^)D, the Strategic Use of New generation antidepressants for Depression, is an assessor-
blinded, parallel-group, multicenter pragmatic mega-trial to examine the optimum treatment strategy for the
first- and second-line treatments for unipolar major depressive episodes. The trial has three steps and two
randomizations. Step I randomization compares the minimum and the maximum dosing strategy for the first-line
antidepressant. Step II randomization compares the continuation, augmentation or switching strategy for the
second-line antidepressant treatment. Step III is a naturalistic continuation phase. The original protocol was
published in 2011, and we hereby report its updated protocol including the statistical analysis plan.
Results: We implemented two important changes to the original protocol. One is about the required sample size,
reflecting the smaller number of dropouts than had been expected. Another is in the organization of the primary
and secondary outcomes in order to make the report of the main trial results as pertinent and interpretable as
possible for clinical practices. Due to the complexity of the trial, we plan to report the main results in two separate
reports, and this updated protocol and the statistical analysis plan have laid out respective primary and secondary
outcomes and their analyses. We will convene the blind interpretation committee before the randomization code is
broken.
Conclusion: This paper presents the updated protocol and the detailed statistical analysis plan for the SUN(^_^)D
trial in order to avoid reporting bias and data-driven results.
Trial registration: ClinicalTrials.gov: NCT01109693 (registered on 21 April 2010).
Update
This paper provides the updated protocol and the de-
tailed statistical analysis plan for the Strategic Use of
New generation antidepressants for Depression, SUN
(^_^)D, randomized controlled trial, a pragmatic mega-
trial examining the optimum treatment strategy for the
first- and second-line treatments for unipolar major
depressive episodes. The original protocol was published
in Trials in 2011 [1], and we hereby report its updated
protocol including the statistical analysis plan, as we
would like to implement two important changes to the
original protocol. One change is about the required sam-
ple size, reflecting the smaller number of dropouts than
had been expected. Another change is in the organization
of the primary and secondary outcomes in order to make
the report of the main trial results as pertinent and inter-
pretable as possible for clinical practices.
The trial completed recruitment of all participants on
13 March 2015, and completion of the last follow-up is
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expected in September 2015. This updated protocol and
statistical analysis plan were drafted without knowledge
of the randomization code, which will not be broken be-
fore acceptance of the current paper for publication.
Trial overview
Trial design
SUN(^_^)D is an assessor-blinded, parallel-group, multi-
center randomized controlled trial [1]. The trial has
three steps with two randomizations (Fig. 1). Randomi-
zations were performed at first recruitment for Step I
(cluster randomization by site) and at start of Step II
(individual randomization). Step I has two arms, in
which sertraline will be started from 25 mg/d and ti-
trated up to 50 mg/d or up to 100 mg/d, the minimum
and the maximum of the standard prescription range in
Japan, respectively. Step II has three arms, in which
sertraline will be continued as in Step I, mirtazapine will
be added to sertraline, or sertraline will be switched to
mirtazapine. In Step III, all the treatments will be at the
discretion of the treating physician.
Treatment of a major depressive episode is commonly
divided into the acute phase treatment, which aims at
the prompt reduction of acute symptoms, and the con-
tinuation treatment, which not only seeks to reduce fur-
ther the symptoms but also to prevent symptom relapses
[2, 3]. The acute phase treatment usually lasts 6 to 12
weeks, and it is recommended that the continuation treat-
ment be continued 4 to 9 months after the acute phase
treatment [2, 3]. In our study, therefore, Steps I and II
represent the acute phase treatment, whereas Step III cor-
responds with the continuation treatment.
Ethics
This study is being conducted in accordance with the
Declaration of Helsinki and its amendments as well as
the Ethics Guideline for Clinical Research (2008 revision,
Ministry of Health, Labor and Welfare, Japan). Written
informed consent has been obtained from each partici-
pant after full explanation of the purpose and the proce-
dures of the study.
This study has been approved by the Ethics Committee
of Kyoto University Graduate School of Medicine (C446),
Institutional Review Board of Nagoya City University
Hospital (45-10-0004), Ethics Committee of Kochi Medical
School (22-96), Ethics Committee of Kumamoto University
Graduate School of Life Sciences (Senshin 1341), Institu-
tional Review Board of Yatsushiro Kosei Hospital, Ethics
Committee of Yuge Hospital (86), Ethics Committee of
Kurume University (11151), Ethics Committee of Saint
Lucia Hospital, Ethics Committee of Hiroshima University
Hospital (Rin 297), Institutional Review Board of The
University of Tokyo Hospital (P2011062-11X), Ethics
Committee of Toho University School of Medicine (23053),
and Institutional Review Board of Hokkaido University
Hospital (Ji 011-0292).
Funding
This trial was funded by a Grant-in-Aid from the Min-
istry of Health, Labor and Welfare, Japan (H22-Seishin-
Fig. 1 Flow diagram of the trial
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Ippan-008) (from April 2010 to March 2012) and by a
research project “Pragmatic Psychopharmacotherapy
Research” of the Japan Foundation for Neuroscience
and Mental Health (from April 2012 to present). The
“Pragmatic Psychopharmacotherapy Research” project
has received donations from Asahi Kasei Pharma, MSD,
Otsuka Pharmaceutical, GlaxoSmithKline, Shionogi, Taisho
Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, Eli-Lilly,
Meiji Seika Pharma, Mochida Pharmaceutical, and Janssen
Pharmaceutical as of May 2015.
Study objectives
As presented in the published protocol [1], the objective
of this trial is to establish the optimum first-line and
second-line antidepressant treatment strategy among pa-
tients with a nonpsychotic unipolar major depressive
episode. As the SUN(^_^)D trial involved two randomi-
zations, we will report the main results of the trial as
two separate reports.
REPORT #1 will be entitled “Optimum Target Dose
for Initial Sertraline Treatment for Depression: The
SUN(^_^)D Trial.”
This report will answer the following clinical question:
Which is a superior dosing strategy for the first-line treat-
ment with sertraline, aiming at the lowest or the highest
of the standard prescription range, through the acute
phase treatment as well as the continuation treatment?
We will compare the following two interventions:
1. Intervention 1: The strategy is to start sertraline at
25 mg/d, with the intention of titrating it up to 50
mg/d where possible by week 3, continuing it up to
week 9, and then prescribing at the treating
physician’s discretion up to week 25.
2. Intervention 2: The strategy is to start sertraline at
25 mg/d, with the intention of titrating it up to 100
mg/d where possible by week 3, continuing it up to
week 9, and then prescribing at treating physician’s
discretion up to week 25.
In order to examine the effect of the choice of the ini-
tial dosing strategy of the first-line treatment with sertra-
line through the acute and continuation treatment
phases, REPORT #1 will focus on the participants in the
blue-shaded cells in Fig. 1.
REPORT #2 will be entitled “Continue, Switch or
Augment after Initial Failure to Remit on First-line
Treatment in Depression: The SUN(^_^)D Trial.”
This report will answer the following clinical ques-
tion: What is the best second-line treatment for
patients with no or partial initial response to the first-
line treatment with sertraline through the acute phase
treatment as well as the continuation treatment?
We will compare intervention 1 with intervention 2,
intervention 2 with intervention 3, and intervention 3
with intervention 1 (that is, all combinations without
any preferential ordering in importance):
1. Intervention 1: The strategy is to continue sertraline
at week 3 and up to week 9, and then prescribing at
the treating physician’s discretion up to week 25.
2. Intervention 2: The strategy is to switch sertraline to
mirtazapine at week 3 and up to week 9, and then
prescribing at the treating physician’s discretion up
to week 25.
3. Intervention 3: The strategy is to add mirtazapine to
sertraline at week 3 and up to week 9, and then
prescribing at the treating physician’s discretion up
to week 25.
REPORT #2 will therefore compare the three interven-
tion arms at double borders in Fig. 1 through the acute




The Patient Health Questionnaire-9 (PHQ9) was developed
as a self-report version of the Primary Care Evaluation of
Mental Disorders (PRIME-MD) [4, 5]. The depression
module of the PHQ is called PHQ9 and consists of the nine
diagnostic criteria items of the DSM-IV. Each item is rated
between 0 = “not at all” through 3 = “nearly every day,”
making the total score range from 0 to 27.
Kroenke and his colleagues [6] have provided the fol-
lowing rules of thumb for interpreting the continuous
PHQ9 scores:
0 to 4 no depression
5 to 9 mild depression
10 to 14 moderate depression
15 to 19 moderately severe depression
20 to 27 severe depression
In this trial, PHQ9 and FIBSER will be administered
four times (at week 1, week 3, week 9 and week 25) by
the blinded central rater via telephone [7].
Frequency, intensity, and burden of side effects rating
The Frequency, Intensity, and Burden of Side Effects
Rating (FIBSER) was originally used in STAR*D [8, 9] as
a global rating scale for side effects. This is an assessor-
rated scale, and the Japanese translation has not under-
gone back translation. Each item is rated in seven grades
of severity.
Yonemoto et al. Trials  (2015) 16:459 Page 3 of 13
Beck depression inventory-II
The Beck Depression Inventory-II (BDI-II) is a 21-item
self-report instrument to measure the severity of depres-
sion [10, 11]. The time frame for evaluation is set to the
past 2 weeks, including the day of assessment. Each item
in the BDI-II has a series of four statements, which de-
scribe symptom severity along an ordinal continuum
from absent or mild (a score of 0) to severe (a score of
3). The total score therefore ranges from 0 through 63.
In this trial, BDI-II will be filled in by the patient at
each visit (unblinded).
Columbia classification algorithm for suicide assessment
The Columbia Classification Algorithm for Suicide As-
sessment (C-CASA) is a classification system that uti-
lizes definitions of suicidality [12]. The C-CASA has
eight categories that distinguish suicidal events from
nonsuicidal events and indeterminate or potentially sui-
cidal events. The scoring is a binary (yes or no) for each
item.
Serious adverse events
A serious adverse event is defined here as “an adverse
event that may lead to death or to enduring severe im-
pairment depending on the patient’s conditions and cir-
cumstances” and will include the following:
1. Death
2. Life-threatening event
3. Hospitalization or the prolongation of
hospitalization
4. Event leading to enduring and severe impairment
and dysfunction
5. Congenital malformation
The scoring is a binary yes or no for each item.
Allowance of timing of outcome assessments
Assessments at week 3, 9 and 25 may be made within
the following time frames after week 1:
1. ± 4 days for assessments at weeks 3 through 9
2. ± 14 days for assessments after week 9
If the allowance is violated, we will report it as a devi-
ation from protocol.
Primary outcome
We conducted two randomizations in this trial, and will
therefore make two corresponding reports, each of
which will have its own primary outcome for the acute
phase treatment as follows:
REPORT #1: Change in PHQ9 from 1 through 9 weeks
REPORT #2: Change in PHQ9 from 3 through 9 weeks
Secondary outcomes
Secondary outcomes for REPORTS #1 and #2 are sum-
marized below from the viewpoint of the acute phase
treatment (up to 9 weeks) and that of the acute through
continuation treatments (up to 25 weeks).
REPORT #1
Report #1 will include the following:
1. For the acute phase treatment
(as an index of effectiveness)
1-1. Change in BDI-II from 1 through 9 weeks
1-2. Proportion of response (50 % or greater
reduction from week 1 in PHQ9) at week 3
and week 9
1-3. Proportion of remission (4 or less on PHQ9)
at week 3 and week 9
(as an index of acceptability and safety)
1-4. Proportion of successful continuation of the
allocated treatment up to week 3 and to
week 9
1-5. Change in FIBSER from 1 through 9 weeks
1-6. Incidence of suicidality as measured with C-
CASA between 1 and 9 weeks
1-7. Incidence of mania, hypomania and mixed
episodes between 1 and 9 weeks
1-8. Incidence of serious adverse events between 1
and 9 weeks.
2. For the acute-phase to continuation treatments,
(as an index of effectiveness)
2-1. Proportion of remission (4 or less on PHQ9)
at week 25
2-2.Change in PHQ9 from 1 through 25 weeks
2-3. Change in BDI-II from 1 through 25 weeks
(as an index of acceptability and safety)
2-4. Time to discontinuation of the allocated
treatment by week 25
2-5. Time to discontinuation of any treatment by
week 25
2-6. Change in FIBSER from 1 through 25 weeks
2-7. Incidence of suicidality as measured with C-
CASA between 1 and 25 weeks
2-8. Incidence of mania, hypomania and mixed
episodes between 1 and 25 weeks
2-9. Incidence of serious adverse events between 1
and 25 weeks
REPORT #2
Report #2 will include the following:
1. For the acute phase treatment,
(as an index of effectiveness)
1-1.Change in BDI-II from 3 through 9 weeks
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1-2. Proportion of response (50 % or greater
reduction from week 1 in PHQ9) at week 9
1-3. Proportion of remission (four or fewer on
PHQ9) at week 9
(as an index of acceptability and safety)
1-4. Proportion of successful continuation of the
allocated treatment up to week 9
1-5. Change in FIBSER from 3 through 9 weeks
1-6. Incidence of suicidality as measured with C-
CASA between 3 and 9 weeks
1-7. Incidence of mania, hypomania and mixed
episodes between 3 and 9 weeks
1-8. Incidence of serious adverse events between 3
and 9 weeks.
2. For the acute-phase to continuation treatments,
(as an index of effectiveness)
2-1. Proportion of remission (4 or less on PHQ9)
at week 25
2-2.Change in PHQ9 from 3 through 25 weeks
2-3. Change in BDI-II from 3 through 25 weeks
(as an index of acceptability and safety)
2-4. Time to discontinuation of the allocated
treatment by week 25
2-5. Time to discontinuation of any treatment by
week 25
2-6. Change in FIBSER from 3 through 25 weeks
2-7. Incidence of suicidality as measured with C-
CASA between 3 and 25 weeks
2-8. Incidence of mania, hypomania and mixed
episodes between 3 and 25 weeks
2-9. Incidence of serious adverse events between 3
and 25 weeks
Sample size and power
The clinical question for REPORT #2 is the main hy-
pothesis of this trial. Previous studies using PHQ9 in the
acute phase treatment of major depression have shown
that, on average, the PHQ9 scores will drop from 15
(SD = 5) at baseline to 10 (SD = 6) at the end of treat-
ment, with a mean change of 5 (SD = 5). We expect a
difference of 20 % (1 point) in the PHQ9 change scores
among the intervention arms and consider this a clinic-
ally meaningful difference in effect. With the alpha error
set at 0.05 and statistical power at 0.80, in order to de-
tect a between-group difference of 1 point (SD = 5) in
the reduction of PHQ9 scores from baseline, we need
522 per group and 1,566 in total for Step II. Assuming a
dropout rate of 10 % and a remission rate of 10 % at
week 3, we need 1,934 participants at Step I.
The sample size required for REPORT #1 was deter-
mined as follows. Assuming an intracluster correlation
coefficient to be 0.05 [13, 14], with alpha error at 0.05
and statistical power at 0.80, to detect a difference of 1
point on PHQ9 (SD = 5), that is, to detect an effect size
of 0.2 at week 9, we need 66 patients at each of 30 sites.
We therefore need 1,980 patients at Step I.
Altogether, we concluded that 2,000 patients would be
needed to have enough statistical power to examine our
primary outcomes for REPORTS #1 and #2.
Datasets to be analyzed
The analyses will be performed according to the intention
to treat (ITT) principle. The ITT population will consist
of all randomized subjects regardless of whether he/she
has received the allocated intervention of interest.
Handling of missing data
We will first tabulate the reasons for missing data, com-
pare the baseline characteristics between participants with
missing data versus without missing data, and check the
types of mechanism of missingness as follows: completely
missing at random, missing at random, and informative
missing (Tables 1 and 2).
Statistical analyses
The draft statistical analysis plan was written by YN, ST
and TAF and was subsequently discussed and approved by
Table 2 Comparison of participants with missing data versus





























Table 1 Reasons for missing data
Reasons for missing data
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the Steering Committee. The statistical analyses will be
performed by YN and independently confirmed by ST.
YN will be responsible for all the analyses. We will use
SAS for the analyses.
Patient flow diagram
The flow of participants will be shown in the Consolidated
Standards of Reporting Trials (CONSORT) Flow diagram
(Flow diagram for REPORT #1 and REPORT #2).
Protocol deviations
Participants with protocol deviations in eligibility (for ex-
ample, when a person with an out-of-range age was
erroneously registered) will be excluded from the ITT
population, with reasons for exclusion being noted. Those
with protocol deviations in treatments and/or assessments
will be tabulated (Tables 3 and 4) and will be included in
the ITTanalysis.
Demographic and baseline clinical characteristics of
participants
Demographic characteristics of all participants will be
described per allocated arm in a table describing the
following variables: age, sex (woman or man), education
(years), job (employed full-time, employed part-time, on
sick leave, housewife, student or no employment), and
marriage (single, never married; single, divorced or sepa-
rated; single, deceased; or married). Clinical characteris-
tics to be presented will include the following: age of
onset at first episode, number of previous depressive epi-
sodes, length of current episode, out- or inpatient status
at time of entry into the study, PHQ9 at baseline, BDI-II
at baseline, and physical comorbidities.




Weeks 3 to 9 Weeks
9 to 25
50 mg 100 mg Continue
sertraline
Augment Switch Remitted
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
B. Treatment deviation
B1. Prohibited concurrent treatments
B2. Impossible to randomize at week 3
B3. No tolerability to sertraline at step 1
B4. Mania at week 1 though week 3
B5. Mania or diagnosis of schizophrenia or dementia at week 3 through 25
C. Stopping intervention and assessment
C1. The participant wishes to stop the protocol treatment.
C2. The trial physician judges that it is difficult to continue the protocol
treatment because of the emergence of serious adverse events (SAE) as
defined below.
C3. The trial physician judges that the risk outweighs the benefit in
continuing the protocol treatment even when no SAE is reported.
C4. The participant becomes pregnant and the trial physician judges that
the risk outweighs the benefit in continuing the protocol treatment.
C5. The trial physician judges that it is inappropriate to continue the
protocol treatment for any other reason.
D.
D1. The participant withdraws consent to receiving protocol assessments,
regardless of whether he/she is continuing the protocol treatment.
E.
E1. Violation of allowance in timing of assessments of outcomes
Table 3 Protocol deviations
A. Treatment adherence Total
N (%)
A1. In sertraline 100 mg group, 100 mg not achieved at week 3
A2. In mirtazapine group, sertraline still used (no zero) at week 7.
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Continuous variables will be presented as mean and
standard deviation or, if a considerable skew is present, as
median and interquartile range. The maximum and the
minimum of the reported values will also be noted. Binary
and categorical variables will be presented as the number
of participants and percentage. The P values will be calcu-
lated for comparisons, if necessary (Tables 5 and 6).
Treatments received
The kinds and amounts of the protocol treatments actu-
ally prescribed will be summarized for each intervention
arm at the following time points: week 0; previous day
of weeks 1, 2, 3, 4, 5, 6, 7, 8, and 9 and previous day of
weeks 13, 17, 21 and 25 (Tables 7 and 8).
Analyses for the primary outcome
For the primary outcome in REPORT #1, we will use
a mixed-model repeated-measures analysis to compare
model-adjusted least-squares means of PHQ-9 at 9
weeks. The model will include the fixed effects of
PHQ-9 score at week 1; all demographic and baseline
clinical variables with statistically significant imbal-
ance between the two arms; treatment (sertraline 50
mg/d versus 100 mg/d); visit and treatment-by-visit
interaction; and clinic/hospital size (whether each site
could be expected to recruit 40 patients or more per
year, a condition used as a stratification variable in
cluster randomization). The random effect will in-
clude the participant and the cluster. Study visit will
be treated as a categorical variable.
The population of interest in this comparison is all
the randomized population under continued/intended
sertraline treatment, including those who have




















Age of onset at first
episode, years,
Number of previous
depressive episodes, N (%)
Length of current episode,
months
Out- or inpatient status
at time of entry, N (%)






Physical conditions, N (%)
No physical comorbidity
….
Table 5 Demographic and baseline clinical characteristics for
REPORT #1
50 mg/d arm 100 mg/d arm
Demographic











Age of onset at first episode, years,
Number of previous depressive
episodes, N (%)
Length of current episode, months
Out- or inpatient status at time of
entry, N (%)






Physical conditions, N (%)
No physical comorbidity
…..
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dropped out of the protocol treatment by week 3,
those who have remitted by week 3 (both of whom
were therefore not randomized for Step II), and one
random third of the remaining patients who have
been randomized to continue on sertraline for Step II
(blue-shaded cells in Fig. 1). In other words, the out-
come data will be missing for patients who have been ran-
domized to mirtazapine augmentation or mirtazapine
switching for Step II. We will therefore use inverse prob-
ability of censoring weighting to account for the presence
of missing data in parameter estimation for the mixed-
models repeated-measures.
We will present parameters estimated from the model
as well as the effect sizes between the treatments as
mean difference (MD) and standardized mean difference
(SMD); in order to calculate SMD, SD of the completers’
endpoint scores will be used (Table 9). We will illustrate
the estimated and actual average courses through the
acute and continuation treatment phases by interven-
tions (Figure and average course).
For the primary outcome in REPORT #2, we will exam-
ine whether the changes in PHQ9 scores from week 3
through week 9 are statistically significantly different
among the sertraline continuation arm, the mirtazapine
augmentation arm and the mirtazapine switch arm. We
will use a mixed-model repeated-measures analysis to
compare model-adjusted least-squares means of PHQ-9 at
9 weeks. The model will include the fixed effects of PHQ-9
score at week 3; treatment (sertraline continuation versus
mirtazapine augmentation versus mirtazapine switch); visit
and treatment-by-visit interaction; stratification variables
((i) site, (ii) whether 50 % or greater reduction on PHQ9 is
achieved or not, and (iii) whether “moderate” or greater
impairment due to side effects is reported on item 4 of
FIBSER); and the Step I treatment (sertraline 50 mg/d ver-
sus 100 mg/d). The random effect will be the participant.
Study visit will be treated as a categorical variable. We will
examine the interaction effect of Step I randomization by
adding the Step II treatment by Step I treatment inter-
action term in the above model.
We will present parameters estimated from the
model as well as the effect sizes between the treat-
ments as mean difference (MD) and standardized
mean difference (SMD): in order to calculate SMD,
SD of the completers’ endpoint scores will be used
(Table 10. ). We will illustrate the estimated and
actual average courses through the acute and continu-
ation treatment phases by interventions (Figure and
average course).
Analyses for the secondary outcomes
We will perform secondary analyses to supplement our
primary analyses and obtain more detailed understanding
of our clinical questions. The secondary analyses will use
models similar to those of the primary analyses. We will
calculate mean difference and their 95 % CI for differences
for continuous outcomes and relative risks (RR) and their
95 % CI for dichotomous outcomes.
We will calculate hazard ratios (HR) in Cox regression
and their 95 % CI for differences in continuation of the
allocated treatment and of any treatment. Cases who
withdrew consent to assessment and cases lost to
follow-up (for example, moving away) will be censored.
In survival analysis, we will check the assumptions of
proportional hazard (Tables 9 and 10 ) (Figure, Average
course and survival curve).








Previous day of Week 4
Previous day of Week 5
Previous day of Week 6
Previous day of Week 7
Previous day of Week 8
Previous day of Week 9
Previous day of Week 13
Previous day of Week 17
Previous day of Week 21
Previous day of Week 25
Table 7 Treatments received for each intervention for REPORT #1
50 mg/d arm 100 mg/d arm
Week 0
Previous day of Week 1
Previous day of Week 2
Previous day of Week 3
Previous day of Week 4
Previous day of Week 5
Previous day of Week 6
Previous day of Week 7
Previous day of Week 8
Previous day of Week 9
Previous day of Week 13
Previous day of Week 17
Previous day of Week 21
Previous day of Week 25
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Subgroup analyses
For REPORT #1, we will conduct the following a priori
specified subgroup analyses: (i) whether the baseline
PHQ9 score was 15 or more (moderate to severe depres-
sion) or not, and (ii) whether the patient had shown
greater or smaller improvement from week 0 to week 1
on sertraline 25 mg/d (split at the median of the ob-
served improvements).
We will analyze subgroups for REPORT #2 according to
the following stratification factors used for randomization
at Step II: (i) whether 50 % or greater reduction on PHQ9
was achieved from week 1 to week 3 or not, and (ii)







Difference, RR, HR (95 % CI),
P value, and adjusted 1, 2,
Difference Difference
Primary PHQ9 total score, mean, (SD,
95 % CI)
Effect size
Model-based coefficient, P value
Secondary1 FIBSER total score, mean,
(SD, 95 % CI)
Effect size











Table 9 Outcomes for REPORT #1
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whether “moderate” or greater impairment due to side ef-
fects was reported on item 4 of FIBSER at week 3, as well
as (iii) which treatment arm of Step I the patient was on.
Sensitivity analyses
For the primary outcomes in REPORTS #1 and #2, we
will conduct the following sensitivity analyses:
1. We will conduct completers’ analyses instead of ITT
analyses.
2. We will conduct the same mixed-model repeated-
measures analyses but with visit included as a
continuous variable. For this analysis, two models
will be compared in which the visit timing is
treated as a linear variable or as a log-
transformed variable, and their respective model
fit index will be reported.
3. We will also conduct the same mixed-model
repeated-measures analyses with the actual
assessment timing, not the scheduled assessment
timing, for the above two models. Their respective
model fit index will also be reported.
For the primary outcome in REPORT #1 we will fur-
ther conduct the following sensitivity analyses.
4. For REPORT #1, we will use analysis of
covariance (ANCOVA) without within-clustered
correlation instead of the mixed effect model with
within-cluster correlations, in order to check the
assumption of statistical property by the simpler
analysis, which do not need such assumptions.
5. For REPORT #1, we will conduct the mixed-model
repeated-measures analyses without covariates, that
is, without demographic and baseline clinical
variables that have shown statistically significant
imbalance between the two arms.
Multiplicity
For each of REPORTS #1 and #2, the significance
level will be set at P < 0.05. All statistical testing will
be two-sided. In REPORT #2, we will compare three
arms and will use Hochberg method for adjustment
of multiplicity [15] in the primary analysis. Only
analyses for the primary outcomes have confirmatory
nature and will be controlled for multiplicity. Sec-
ondary analyses and secondary outcomes will not be
adjusted for multiplicity, because these analyses have
explanatory and supplemental nature for the primary
analyses.
Evaluation of blinding of outcome assessment
We will calculate kappa coefficients in treatment
guesses for week 3, 9 and 25 assessments in order to
ascertain the assessors’ blindness to the allocated
treatments (Tables 11 and 12).
Blind interpretation committee
The statistical analysis report will present the primary
results for REPORTS #1 and #2 without breaking the
randomization to the writing committee. The writing
committee will develop interpretations of the results
and associated conclusions assuming for REPORT #1
that Treatment A is the lower dose, and then assuming
Treatment B is the lower dose. Similarly, for REPORT
#2, the interpretations will be developed assuming that
Treatment A is any one of the three possibilities, as
with Treatment B and C. These interpretations will be
recorded, signed by the participants and made public
on the study web site at that time. The randomization
code will then be broken, the correct interpretation will
be chosen, and the manuscript will be finalized accord-
ingly [16, 17].
Summary of changes from the original protocol
In the original protocol [1], we had specified the follow-
ing primary and secondary outcomes for each of Steps I
through III.
Table 11 Blinding at week 3
Actual 50 mg/d 100 mg/d
Guess
50 mg/day at week 3
100 mg/day at week 3
Continue sertraline at weeks 9 or 25
Augment with mirtazapine at weeks 9 or 25
Switch to mirtazapine at weeks 9 or 25
Remitted at weeks 9 or 25





50 mg/day at week 3
100 mg/day at week 3
Continue sertraline at
weeks 9 or 25
Augment with mirtazapine
at weeks 9 or 25
Switch to mirtazapine at
weeks 9 or 25
Remitted at weeks 9 or 25
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In this updated protocol, we have merged Step I with
Step IIIa and Step II with Step IIIb into two main reports
in order to present the results of this complex trial in the
most clinically informative way. These two reports will
focus on Step I randomization and Step II randomization,
respectively, and both will focus on the acute phase treat-
ment up to 9 weeks as their primary outcome but supple-
ment this with other benefit and harm outcomes for the
Step I
Patients: Patients with non-psychotic unipolar major depressive episode
who had not received treatment for the index episode before starting
sertraline and who tolerate sertraline at 25 mg/d
Exposure 1: Strategy to titrate sertraline up to the maximum of the
effective range, that is, 25 mg/d≥ 50 mg/d≥ 100 mg/d
Exposure 2: Strategy to titrate sertraline up to the minimum of the
effective range, that is, 25 mg/d≥ 50 mg/d≥ 50 mg/d
Outcomes: The primary outcome is the change in PHQ9 scores at week
1 through week 3
The secondary outcomes include:
Change in BDI2 scores at week 1 through week 3
Proportion of remission (four fewer on PHQ9) at week 3
Proportion of response (50 % or greater reduction on PHQ9) at week 3
Proportion of successful continuation of the allocated treatment up to
week 3
Change in FIBSER at week 1 through week 3
Change in PHQ9 at week 1 through week 9
Change in BDI2 at week 1 through week 9
Proportion of remission (four or fewer on PHQ9) at week 9
Proportion of response (50 % or greater reduction on PHQ9) at week 9
Proportion of successful continuation of the allocated treatment up to
week 9
Change in FIBSER at week 1 through week 9
Suicidality as assessed with C-CASA between week 1 and week 9
Manic/hypomanic/mixed episode between week 1 and week 9
Serious adverse events between week 1 and week 9
Step II
Patients: Patients whose major depressive episode did not remit (five or
more on PHQ9) at week 3 to the first-line treatment with sertraline
Exposure 1: Continue sertraline 50 mg/d or 100 mg/d for 6 more weeks
Exposure 2: Augment sertraline with mirtazapine 15 to 45 mg/d
Exposure 3: Switch to mirtazapine 15 to 45 mg/d
Outcome: The primary outcome is the change in PHQ9 at week 4
through week 9
The secondary outcomes include:
Change in BDI2 at week 4 through week 9
Proportion of remission (four or fewer on PHQ9) at week 9
Proportion of response (50 % or greater reduction on PHQ9) at week 9
Proportion of successful continuation of the allocated treatment up to
week 9
Change in FIBSER at week 4 through week 9
Suicidality as assessed with C-CASA between week 3 and week 9
Manic/hypomanic/mixed episode between week 3 and week 9
Serious adverse events between week 3 and week 9
Step IIIa (exploratory analysis of continuation treatment for Step I)
Patients: Patients with nonpsychotic unipolar major depressive episode
who had not received treatment for the index episode before starting
sertraline and who tolerate sertraline 25 mg/d
(Continued)
Exposure 1: Strategy to titrate sertraline up to the maximum of the
effective range, that is, 25 mg/d≥ 50 mg/d≥ 100 mg/d by week 3, then
allocated to continue sertraline between week 3 and week 9, then
treated at the discretion of the trial physician
Exposure 2: Strategy to titrate sertraline up to the minimum of the
effective range, that is, 25 mg/d≥ 50 mg/d≥ 50 mg/d by week 3, then
allocated to continue sertraline between week 3 and week 9, then
treated at the discretion of the trial physician
Outcome: The primary outcome is the proportion of patients who
continue the allocated treatment up to week 25 and are in remission
(4 or less on PHQ9) at week 25
The secondary outcomes include:
Proportion of patients who continue the allocated treatment up to
week 25 and are showing response (50 % or greater reduction on
PHQ9) at week 25
Rate of continuation of allocated treatments up to week 25
Change in PHQ9 at week 1 through week 25
Change in BDI2 at week 1 through week 25
Suicidality as assessed with C-CASA between week 1 and week 25
Manic/hypomanic/mixed episode between week 1 and week 25
Serious adverse events between week 1 and week 25
Step IIIb (exploratory analysis of continuation treatment for Step II)
Patients: Patients whose major depressive episode did not remit (five or
more on PHQ9) at week 3 to the first-line treatment with sertraline
Exposure 1: Continue sertraline 50 mg/d or 100 mg/d for 6 more weeks,
then treated at the discretion of the trial physician
Exposure 2: Augment sertraline with mirtazapine 15 to 45 mg/d up to
week 9, then treated at the discretion of the trial physician
Exposure 3: Switch to mirtazapine 15 to 45 mg/d up to week 9, then
treated at the discretion of the trial physician
Outcome: The primary outcome is the proportion of patients who
continue the allocated treatment up to week 25 and are in remission
(four or fewer on PHQ9) at week 25
The secondary outcomes include:
Proportion of patients who continue the allocated treatment up to
week 25 and are showing response (50 % or greater reduction on
PHQ9) at week 25
Rate of continuation of allocated treatments up to week 25
Change in PHQ9 at week 4 through week 25
Change in BDI2 at week 4 through week 25
Suicidality as assessed with C-CASA between week 3 and week 25
Manic/hypomanic/mixed episode between week 3 and week 25
Serious adverse events between week 3 and week 25
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acute phase treatment, as well with benefit and harm out-
comes for the continuation treatment up to 25 weeks.
REPORT #1 will examine the clinical questions for
Step I through Step IIIa, as originally postulated in the
published protocol. For this report, however, we have
changed the primary outcome from “Change in PHQ9
from 1 through 3 weeks” to “Change in PHQ9 from 1
through 9 weeks” (which was one of the secondary out-
comes in the original protocol), in order to fully examine
our clinical question comparing the 50 mg/day arm and
100 mg/day arm up to the end of the acute treatment
phase. Week 9 was chosen as the primary outcome
because the acute phase treatment usually is considered
to last 6 to 12 weeks [2, 3]. In order to focus on the ef-
fect of the choice of the initial dosage of the first-line
treatment with sertraline through the acute treatment
phase as defined, we will concentrate on those who did
not remit and were subsequently randomized at week 3
to continue on sertraline (hence, a random third of those
who had not remitted by week 3), those who had remit-
ted and were therefore continued on sertraline, and
those who had dropped out of the protocol treatment by
week 3 and subsequently received treatments at physi-
cian’s discretion, in order to abide by the ITT principle
for Step I randomization (see blue cells in Fig. 1).
REPORT #2 will deal with the clinical question for
Step II and Step IIIb, as originally postulated in the pub-
lished protocol, and has set the primary outcome for
Step II as its primary outcome.
The required sample size at Step I remained the same
for REPORT #1 by assuming the same magnitude to
effect to detect at week 9 instead of at week 3. The sam-
ple size required at Step II for REPORT #2 also
remained the same; however, we reduced the initial sam-
ple size to be recruited into Step I in order to ensure this
sample after we reviewed the observed proportion of
patients who had entered into Step I but subsequently
dropped out of the protocol treatment and could not be
randomized at Step II (from 20 % to 10 %).
All these changes were discussed and agreed upon by
the Steering Committee of the SUN(^_^)D trial before
the randomization code is broken.
Conclusion
This paper presents the updated protocol and the detailed
statistical analysis plan for the SUN(^_^)D trial in order to
avoid risks of reporting bias and data-driven results. Due
to the complexity of the trial, we plan to report the main
results of the trial in two reports, and this updated proto-
col and statistical analysis plan indicate the respective pri-
mary and secondary outcomes and their analyses.
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